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ABSTRACT 
The ARTemis Trial tested standard neoadjuvant chemotherapy (NAC) ± 
Bevacizumab (Bev) in the treatment of HER2 negative early breast cancer. We 
compare data from central pathology review with report-review and also the reporting 
behaviour of the two central pathologists. 
800 women with HER2-negative early invasive breast cancer were recruited. 
Response to NAC± Bev was assessed from local pathology reports for pathological 
complete response (pCR) in breast and axillary lymph nodes. Tissue sections from 
the original core biopsy and surgical excision were centrally reviewed by one of two 
trial pathologists blinded to the local pathology reports. Pathologists recorded the 
response to chemotherapy descriptively and also calculated residual cancer burden 
(RCB).  10% of cases were double-reported to compare the central pathologists’ 
reporting behaviour. 
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Full sample retrieval was obtained for 681 of the 781 patients (87%) who underwent 
surgery within the trial and were evaluable for pCR. 483 (71%) were assessed by JT, 
and 198 (29%) were assessed by EP. RCB calculations were possible in 587/681 
(86%) of the centrally reviewed patients, since 94/681 (14%) had positive sentinel 
nodes removed before NAC thus invalidating RCB scoring. Good concordance was 
found between the two pathologists for RCB classes within the 65-patient quality 
assurance exercise (kappa 0.63 (95%CI 0.57-0.69)). Similar results were obtained 
for the between-treatment arm comparison both from the report-review and the 
central pathology-review. For pCR, report-review was as good as central pathology 
review but for minimal residual disease, report-review overestimated the extent of 
residual disease.  
In the ARTemis Trial central pathology review added little in the determination of 
pCR but had a role in evaluating low levels of residual cancer burden. Calculation of 
RCB proved to be a simple and reproducible method of quantifying response to NAC 
as demonstrated by performance comparison of the two pathologists.  
 
Funding: Cancer Research UK (CRUK/08/037), Roche, Sanofi -Aventis. 
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The ARTemis trial is an open-label, randomised, phase 3 trial assessing the efficacy 
of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, 
and cyclophosphamide, for women with HER2-negative early breast cancer. Its 
primary endpoint was pathological complete response (pCR), defined as the 
absence of invasive disease in the breast and axillary lymph nodes. Initially, the two 
randomised arms of the trial were compared in terms of rates of pCR as determined 
by a two-reader blinded review of local pathology reports.1  In addition a central 
pathology review and a large-scale two-stage pathology quality assurance exercise 
was undertaken. Thereby the accuracy of this commonly used primary endpoint in 
neoadjuvant chemotherapy breast cancer trials was assessed and compared with 
the two-reader report-review which until now has been the standard used by this 
group. 2  In addition the reliability of central specimen review has been investigated 
by independent double-reading of residual cancer burden (RCB) categories carried 
out by the two central pathologists in a subset of cases. This allows us to report on 
the comparison between assessment of local pathology report and central pathology 
review of original diagnostic material and also the reporting behaviour of the two 
reviewing pathologists. Although central pathological review has been carried out in 
studies reporting major centre results 3 as far as the authors are aware this is the 
first report of central pathology review of pCR with RCB scoring and category 
definition, carried out as part of a multi-centre large randomised phase 3 trial. 
 
PATIENTS AND TREATMENTS 
Between May 2009 and January 2013, the ARTemis trial recruited 800 women ≥18 
years old with newly diagnosed HER2-negative early invasive breast cancer 
(radiological tumour size >20 mm, with or without axillary involvement). Patients with 
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inflammatory cancer, T4 tumours with direct extension to the chest wall or skin, and 
ipsilateral supraclavicular lymph node involvement were also eligible with any size of 
primary tumour. Full eligibility criteria details have been described in detail 
elsewhere.1  Patients were randomised from 66 UK sites and assigned, via a central 
computerised minimisation procedure, to three cycles of docetaxel (100 mg/m² once 
every 21 days) followed by three cycles of fluorouracil (500 mg/m²), epirubicin (100 
mg/m²), and cyclophosphamide (500 mg/m²) once every 21 days (D-FEC), without or 
with four cycles of bevacizumab (15 mg/kg) (Bev+D-FEC). 781 patients (98% of the 
randomised 800) underwent surgery following their neo-adjuvant treatment and 
could be assessed, via local pathology reports, for the primary endpoint of absence 
of invasive breast cancer in the breast and axillary lymph nodes. 
 
METHODS 
Diagnostic and surgical excision histopathology slides were requested from the 
relevant participating sites for all of the 781 evaluable patients. All retrieved cases 
underwent central independent review, blinded to the local histopathology report, by 
an experienced breast histopathologist with a special interest in neoadjuvant clinical 
trials (JT & EP) between June 2011 and March 2016. The reviewing pathologist was 
not the same as the pathologist who had previously assessed the slides locally, 
and/or would have access to the histopathology results at their hospital. Any missing 
slides or additional relevant operations (e.g. sentinel lymph node biopsy) were re-
requested as necessary. The variables recorded were maximum invasive tumour 
size in two dimensions, whole tumour size (including DCIS) in two dimensions, post 
treatment tumour grade, presence of lymphovascular invasion, presence and nature 
of in situ disease, percentage tumour cellularity, percentage cellularity that is in situ 
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disease, total number of lymph nodes, number of positive lymph nodes and size of 
largest nodal metastasis.  
 
As well as assessing the validity of the findings from the blinded review of local 
pathology reports, an inter-pathologist reproducibility exercise was also undertaken. 
For this, a randomly chosen 10% of patients had samples reviewed by both 
pathologists for determination of levels of agreement between central review 
findings. To simplify this exercise variables were restricted to those required to 
calculate the RCB score: invasive size (length and width), percent tumour cellularity, 
percent of tumour that is DCIS, size of largest nodal metastasis and number of 
positive nodes.4 The 10% sample was randomly chosen, whilst ensuring a 
representative RCB class split, as recorded by the first pathologist’s reviews. 
 
The results of the central pathology review were also compared with the outcome 
results as determined by the central review of the original histopathology reports 
from the source laboratory. In particular, we compared rates of pCR and minimal 
residual disease (MRD) as determined by formal assessment of the RCB and by 
interpretation of the histopathology. The local pathologists were not given any formal 
reporting guidelines specifically for this trial. 
 
STATISTICAL METHODS 
Agreement between the two pathologists’ RCB classes, and also between central 
review and local reports in determination of pCR, was undertaken using the kappa 
statistic. Agreement between the two pathologists in terms of RCB scores and its six 
components were scrutinised using Bland-Altman plots and assessed using overall 
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concordance correlation coefficient (CCC) 5 Comparison of patient characteristics 
between groups was undertaken using chi-squared tests with continuity correction 
where appropriate. Logistic regression was used to assess the effect of randomised 
treatment arm on pCR rates, after adjustment for stratification factors. 
 
RESULTS 
A total of 22,916 slides from 727 patients were reviewed. Full sample retrieval was 
obtained for 681 (87%) of the 781 ARTemis patients who underwent surgery within 
the trial and were evaluable for the primary endpoint of pCR. 483/681 patients (71%) 
were assessed by JT, and 198/681 patients (29%) by EP. The maximum number of 
slides per patient was 164; median 29 slides.  94/681 patients (14%) had a positive 
pre-chemotherapy sentinel lymph node biopsy (SLNB) thus invalidating the 
calculation of an RCB score at surgery. RCB scores and classes were thus 
calculated on the remaining 587 patients (75% of the 781). Patient characteristics of 
the 587 patients with assessable RCB appeared representative of the trial sample as 
a whole (Table 1). 
 
INTER-RATER REPRODUCIBILITY OF PATHOLOGISTS 
65 patients were double reviewed by JT and EP. The 65 patients were 
representative of the 587 sample as a whole in terms of patient characteristics 
(Table 1) and the random sampling technique determined that they were also 
representative in terms of RCB class as recorded by the first pathologist’s central 
review. 
 
RCB class 
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The two pathologists showed very similar reporting profiles for RCB class (observed 
frequencies of RCB 0:1:2:3 being 14:9:32:10 for pathologist 1 and 13:9:34:9 for 
pathologist 2) (Table 2). In 52/65 (80%) of patients there was agreement on RCB 
class, and in 13/65 (20%) where there was disagreement none were more than one 
RCB class different. A good level of agreement was observed over all RCB classes 
(Kappa 0.70 (95%CI 0.55-0.84)) (Figure 1). No differences were found between 
patient groups where JT and EP agreed on RCB class (n=52) or disagreed (n=13), in 
terms of randomised treatment arm or stratification variables (age, ER status, tumour 
size, clinical involvement of axillary nodes, locally advanced/inflammatory disease 
data not shown). 
 
RCB score 
For the 13 patients where there was disagreement in RCB class, the majority of 
disagreements were due to the two pathologists’ RCB scores falling just either side 
of the published RCB score cut-points of 1.36 and 3.28 (Figure 2). There was good 
overall concordance in RCB score (CCC 0.75 (95%CI 0.40-0.91)), with the average 
discrepancy in RCB score being of the magnitude 0.245 (IQR 0.135-0.501, range 
0.085-1.840).  
 
Components of the RCB score 
Focusing on the 13 patients where the two pathologists differed in RCB class 
assignment, the greatest inter-rater variability was in the assessment of percentage 
of DCIS within the tumour (CCC -0.04 (95%CI -0.30-0.21)) and, to a lesser extent, in 
the assessment of invasive size [CCC 0.20 (95%CI -0.12–0.47) for width and CCC 
0.35 (95%CI -0.11-0.68) for length] and percent of tumour cellularity (CCC 0.30 
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(95%CI -0.05-0.59)). The strongest agreement was observed in identification of 
number of positive nodes (CCC 0.95 (95%CI 0.85-0.98)) followed by size of the 
largest nodal metastasis (CCC 0.74 (95%CI 0.37-0.91)).  
 
Sources of discrepancy 
Seven cases where there was a disagreement in RCB class due to substantial 
differences in size measurement, cellularity or nodal status were reviewed again with 
joint discussion by the two pathologists. Sources of discrepancy included 
interpretation of multiple tumour foci as one lesion or multiple lesions, measurement 
of lesion size from single slides or estimating total number of slides, inclusion of pre-
treatment SLN metastases in the RCB calculation, errors in measurement, and 
interpretation of degenerate cells in post treatment lymph nodes as metastasis or 
not. 
 
CENTRAL REVIEW OF PATHOLOGY SPECIMENS VS REVIEW OF LOCAL 
PATHOLOGY REPORTS: INTER-METHOD RELIABILITY 
Both methods determined similar levels of pCR in the 587 patients where both 
assessment results were available; 121 (21%) with RCB class 0 from central 
pathology review and 119 (20%) reported as pCR from local pathology report (Table 
3). A good level of agreement was observed between the two methods’ findings 
when grouped as the 3 levels of RCB 0 (pCR) vs RCB 1 (MRD) vs RCB 2/3 
(Moderate/extensive disease) (kappa 0.63 (95%CI 0.57-0.69) (Figure 3). However, 
for 6 patients, the level of disagreement was by more than one category (1 patient 
with pCR from the report-review but RCB Category 2 from specimen review, and 5 
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patients with Moderate/extensive disease from the report-review but with RCB 
category 0 from the specimen review.) 
 
Slides for 5 of the 6 cases were available for second review by one of the 
pathologists (EP). Sources of discrepancy included not receiving all the tumour 
slides for review (2 cases) and interpretation of residual tumour as DCIS or invasive 
disease (1 case). In one case, the second review agreed with the histopathology 
report (residual tumour) rather than the central review (pCR). In another case called 
pCR on central review, the discrepancy appears to be due to inconsistency in the 
original report in calling tumour cells in the node viable and non-viable; both central 
reviewers thought this represented an area of necrosis. 
 
 
ARTemis PRIMARY ENDPOINT RESULTS 
The ARTemis trial’s primary endpoint was previously reported using the local 
pathology report-reviews on 781 patients and showed significantly more Bev+D-FEC 
patients achieving a pCR compared with D-FEC patients: 22% (95%CI 18–27) of 
388 Bev+D-FEC patients compared with 17% (95%CI 13–21) of 393 D-FEC patients 
(adjusted p=0.03) (Table 4A).1  Using the RCB categories from the central pathology 
specimen review the results remained the same: 25% (95%CI 20–30) of 290 Bev+D-
FEC patients achieved an RCB 0 compared with 16% (95%CI 12–21) of 297 D-FEC 
patients (adjusted p=0.02) (Table 4B). 
 
Likewise previously, using local pathology report-reviews, pCR rates had been found 
to differ significantly across both ER status (ER negative 38% [95% CI 32–45], 
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weakly positive 41% [29–53], strongly positive 7% [5–9]; p<0.0001), and tumour 
grade (grade 1/2 7% [4–11], grade 3 29% [25–34]; p<0.0001). Using the central 
pathology specimen review, similar results were found for rates of RCB 0; ER 
negative 39% [95% CI 32–46], weakly positive 35% [23–48], strongly positive 7% [5–
11] (p<0.0001) and grade 1/2 7% [4–12], grade 3 31% [26–37] (p<0.0001).   
 
DISCUSSION 
This review focused on the presence or absence of pCR in the excision specimen 
including the presence of residual DCIS. Local pathologists were not given reporting 
proformas or guidelines for assessment of response which have been shown to aid 
concordance between pathologists in clinical trials. 6 Because the reviewing 
pathologists were assessing the original sections in the overwhelming majority of 
cases analytical issues do not impinge on this central review although differences in 
practice among different local laboratories would necessitate caution in drawing any 
comparison between centres. 
 
In this review the pathologists were blinded to the macroscopic description and 
therefore had to reconstruct the tumour bed dimensions from the slides as best they 
could.  Normally a pathologist would record a block map to aid reconstruction of the 
tumour area when viewing the slides, and this was highlighted as being of particular 
importance for accurate assessment of response in the recent BIG-NABCG working 
group recommendations.7  In some cases the tumour bed was present on 
megaslides and this made assessment much easier. The assessment of tumour bed 
size is often not straightforward following neoadjuvant chemotherapy because the 
tumour is poorly defined macroscopically, and it can be difficult to determine the 
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tumour boundaries histologically. Tumour cellularity can be very heterogeneous, and 
is also difficult to assess in spite of the availability of online guidance tools 7  8 and 
there is inconsistency amongst pathologists in these assessments.9  Agreement 
about pCR should however be good and will only usually cause difficulty if small 
residues of tumour cells are overlooked, or if there is difficulty in interpreting in situ 
from invasive disease. Although in this study the best level of agreement in the 
reviewing pathologists’ cross-over study was of numbers of lymph nodes this also is 
not always easy to determine without the macroscopic description. In some cases 
the local pathologist had written on the slide to state the number of nodes present. 
The concordance between the two pathologists is better than recorded in a recent 
review of consistency of reporting of RCB and replicates the finding that the reporting 
of the lymph node component of the score is more reproducible. 9 Given the 
limitations of this study detailed above with lack of access to source reports and 
block descriptions, the RCB is shown to be a very robust system for quantifying 
residual disease in the clinical trial context. 
 
The central pathology review was immensely labour-intensive. The maximum 
number of slides submitted for a single case was 164 (median 29 per case). At best 
it was only possible to review three or four cases per hour. Not only was it time-
consuming for the pathologists but it also placed a burden on local pathology 
departments retrieving slides and a considerable logistic burden for the Trials Office. 
One must question whether the exercise was worth the effort given that there was no 
clinically significant numerical change in the end results. However, one cannot 
generalise about central pathology review. In some trials central review is used at 
the outset to confirm eligibility whether this be Her-2 or ER status for example or a 
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particular tumour type e.g. triple negative breast cancer. In the ALTTO Trial both 
Her-2 and ER status were changed following central re-testing in 5 – 15% of cases.10  
An important distinction must be drawn here between re-testing, potentially using 
different reagents and conditions, and the review of original diagnostic material. In 
ARTemis we accepted a patient’s eligibility as reported but reviewed critically the 
endpoint which was very specifically pathological. 
 
Review of pathology reports by the two principal investigators was made more 
difficult by a lack of standardisation of how local reports were written – not all units 
use easy-to-read synoptic reports. Moreover the majority of standardised reports are 
designed for the adjuvant setting without specific fields for the additional variables 
that need to be recorded post neoadjuvant therapy, such as tumour cellularity and 
fibrosis in lymph nodes. Standardisation of routine reporting in clinical practice for 
neoadjuvant cases has been addressed recently by an international working group 
which should make this easier when designing future clinical trials.11 It is possible 
that should such standardisation be adopted, a measure of response such as RCB 
could be calculated locally. Also, although there is some evidence that pathologists 
are better at assessing chemotherapy response by reading pathology reports than 
are practicing clinicians12 this was not borne out by our data.  It was evident on 
review of some of the cases where there were discrepancies between report-review 
and central review that this was due to missing slides. In this trial the two 
pathologists were involved in the resolution of disputed MRDs on report-review and 
were probably helpful in that area but MRD was not an end point of the trial. 
Furthermore one must urge caution in trying to make direct comparisons between 
RCB and more descriptive approaches to assessment of response to NAC 
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particularly in equating RCB1 with MRD. RCB1 is strongly dependent on low tumour 
cellularity while MRD as determined by the report review, where there was often no 
information on comparison of pre and post treatment tumour cellularity, was heavily 
influenced by residual tumour size and these are not always the same. 
 
The literature on central pathology review of clinical trials is limited. The NSABP 
requires central pathology review for its randomised clinical trials and central 
reviewers are trained to operate with 90% concordance on pathological features 
compared with 65% concordance between local and central reporting in the NSABP 
B-18 trial for example. 13 Recently reported central review of bone marrow fibrosis 
showed a concordance of 58% between central and local reporting whereas a 
central panel of three reviewing pathologists achieved consistency of 88% for all 
three pathologists and 98% for two.14 However we were unable to find any reports of 
central pathology review in the context of neoadjuvant breast cancer trials. 
 
We chose RCB as our method of measuring chemotherapy response primarily 
because it gave a numerical score which proved particularly convenient when it 
came to the cross-over study between the two pathologists. Its principal shortcoming 
is the lack of comparison with the baseline core biopsy but from a clinical point of 
view the tumour burden following chemotherapy is a sensible feature to measure 
and has been shown to correlate well with outcomes at 10 years follow up.15  One of 
the important aspects of ARTemis is the future programme of translational research 
and that has required sections from core biopsies, excised tumours and nodes to be 
marked up for future tissue sampling. A pathologist would certainly be required to 
support that aspect of a future trial. The central review process described here also 
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provides great confidence in the recorded ARTemis endpoints, thus supporting 
subsequent translational work aimed at understanding the determinants of individual 
tumour response and the correlations of that with long term outcomes. Recently it 
has been shown that combining RCB with Ki67 measurements further increases the 
predictive power of this tool. 16  Also there is a growing interest in either post-neo-
adjuvant studies, or allowing patients to enter other studies post-NACT which means 
that where low volumes of residual disease are permitted in such studies, perhaps 
caution is needed about relying on local reporting – whereas for pCR or bulk residual 
disease one can probably rely on local reporting.
  
CONCLUSION 
Central pathology review of the ARTemis trial has allowed a direct comparison with 
report-review and has shown that when the primary end point of the trial pCR, is 
compared, the two methods are equally effective. Central pathology review has a 
place in the assessment of minimal residual disease but if that is not an agreed pre-
specified trial end point there is little extra value in doing this. Learning from the 
experience of ARTemis, future neoadjuvant clinical trials could be improved by 
training in the routine calculation of RCB. Also, standardised routine reporting using 
report templates would greatly assist in report-review.17 Such training might provide 
more robust reporting of RCB categories, facilitating future clinical management, 
when current and planned trials of adjuvant treatment in patients not achieving a 
pCR to neoadjuvant therapy come to fruition.  
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Table 1: Patient characteristics 
 
Table 2: RCB categories for the 65 patients, by the two pathologists 
 
Table 3: Levels of residual cancer at surgery, from the two assessment methods for 
the 781 patients 
Table 4A: Treatment arm comparison using local pathology report review data 
(n=781 patients) 1  
Table 4B: Treatment arm comparison using central pathology specimen review data 
(n=587 patients) 
 
Figure 1: Level of agreement across two pathologists’ rating of RCB class 
Figures 2A and 2B: Inter-rater reliability of pathologists’ RCB scores, where there is 
disagreement in RCB class (n=13 patients) 
2A – Pathologist 1 v Pathologist 2 RCB Scores 
2B – Average of the two pathologist’s RCB Scores 
Figure 3: Level of agreement across the two methods of review 
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Table 1: Patient characteristics 
 
 
Full trial population 
(n=800) 
Central pathology 
review sample 
(n=587) 
Inter-rater reliability 
sample (n=65) 
 N (%) N (%) N (%) 
Randomised treatment                                    Bev+D-FEC 399 (50%) 290 (49%) 29 (45%) 
 D-FEC 401 (50%) 297 (51%) 36 (55%) 
Age <50 years old 543 (68%) 393 (67%) 44 (68%) 
 >50 years old 257 (32%) 194 (33%) 21 (32%) 
ER status Negative (Allred score 0-2) 248 (31%) 194 (33%) 18 (28%) 
 Weakly positive (Allred score 3-5) 75 (9%) 60 (10%) 10 (15%) 
 Strongly positive (Allred score 6-8) 477 (60%) 333 (57%) 37 (57%) 
Tumour size <50mm 635 (79%) 472 (80%) 54 (83%) 
 >50mm 165 (21%) 115 (20%) 11 (17%) 
Clinical involvement of axillary nodes No 383 (48%) 288 (49%) 38 (58%) 
 Yes 417 (52%) 299 (51%) 27 (42%) 
Inflammatory or locally advanced disease or both No 651 (81%) 484 (82%) 51 (78%) 
 Yes 149 (19%) 103 (18%) 14 (22%) 
RCB category * 0 - 121 (21%) 14 (21%) 
 1 - 90 (15%) 9 (14%) 
 2 - 290 (49%) 33 (51%) 
 3 - 86 (15%) 9 (14%) 
* RCB category is only known for those patients included in the central pathology review sample 
Table 2: RCB categories for the 65 patients, by the two pathologists 
 
 Pathologist 1  
Pathologist 2 RCB Cat 0 RCB Cat 1 RCB Cat 2 RCB Cat 3 Total 
RCB Cat 0 13 - - - 13 
RCB Cat 1 1 5 3 - 9 
RCB Cat 2 - 4 27 3 34 
RCB Cat 3 - - 2 7 9 
Total 14 9 32 10 65 
 
Table 3: Levels of residual cancer at surgery, from the two assessment methods for the 781 patients 
 
 Central specimen review  
Local pathology report review RCB Cat 0 RCB Cat 1 RCB Cat 2 RCB Cat 3
Not 
available Total 
pathCR * 109 9 1 0 34 153 
MRD 7 25 29 0 16 77 
Moderate/extensive residual disease 5 56 260 86 144 551 
Total 121 90 290 86 194 781 
 
* pCR in all breast tumours and absence of disease in all removed axillary lymph nodes (ypT0/Tis ypN0) 
Shaded cells indicate agreement 
Table 4A: Treatment arm comparison using local pathology report 
review data (n=781 patients) 1  
 
 DFEC Bev+DFEC  
Local pathology report review % (95%CI) % (95%CI) p * 
 
pCR in all breast tumours AND absence of 
disease in all removed ax LNs (ypT0/Tis ypN0) 
(n=66/393) 
17% (13-21%)
(n=87/388) 
22% (18-27%)
 
0·03
    
ER neg (Allred 0-2)  (n=241) 31% (23-40) 45% (36-55)  
ER weak pos (Allred 3-5)    (n=74) 30% (16-47) 51% (34-68)  
ER strong pos (Allred 6-8)  (n=466) 7% (4-11) 6% (3-10)  
   
‡Grade 1/2   (n=293) 8% (5-14) 6% (3-11)  
Grade 3   (n=403) 23% (17-29) 36% (29-43)  
* Adjusted for the five stratification variables 
‡Tumour grade of each patient’s largest breast tumour at baseline. 
  
Table 4B: Treatment arm comparison using central pathology specimen 
review data (n=587 patients) 
 DFEC Bev+DFEC  
Central pathology review % (95%CI) % (95%CI) p * 
 
RCB 0 
(n=49/297) 
16% (12-21%)
(n=72/290) 
25% (20-30%)
 
0·02
    
ER neg (Allred 0-2)  (n=194) 33% (24-44%) 45% (35-55%)  
ER weak pos (Allred 3-5)    (n=60) 22% (9-42%) 45% (28-64%)  
ER strong pos (Allred 6-8)  (n=333) 6% (3-11%) 8% (4-14%)  
   
‡Grade 1/2   (n=216) 9% (4-16%) 6% (2-12%)  
Grade 3   (n=313) 23% (17-31%) 39% (32-47%)  
* Adjusted for the five stratification variables 
‡Tumour grade of each patient’s largest breast tumour at baseline. 
 
